Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Dulaglutide
Drug: Placebo

First Posted Date: 2016-04-25

Last Posted Date: 2019-09-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 159

Registration Number: NCT02750410

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tama, Japan
🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yokohama, Japan

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Abemaciclib
Drug: Prophylactic Loperamide
Drug: Tamoxifen

First Posted Date: 2016-04-21

Last Posted Date: 2025-01-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 234

Registration Number: NCT02747004

Locations: 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇦🇷
Clinica Viedma, Viedma, Río Negro, Argentina

and more 56 locations

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Phase 1

Completed

Conditions: Advanced Cancer
Colorectal Cancer
Mantle Cell Lymphoma

Interventions: Drug: Ramucirumab
Drug: Abemaciclib
Drug: Merestinib

First Posted Date: 2016-04-20

Last Posted Date: 2019-03-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 23

Registration Number: NCT02745769

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: LY2510924
Drug: Durvalumab

First Posted Date: 2016-04-13

Last Posted Date: 2019-08-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 9

Registration Number: NCT02737072

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Prexasertib

First Posted Date: 2016-04-13

Last Posted Date: 2020-03-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 133

Registration Number: NCT02735980

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

and more 14 locations

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Galunisertib
Drug: Durvalumab

First Posted Date: 2016-04-12

Last Posted Date: 2019-08-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 37

Registration Number: NCT02734160

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇮🇹
Ospedale Policlinico Giambattista Rossi, Borgo Roma, Verona, Italy
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 8 locations

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis

Phase 3

Completed

Conditions: Psoriasis
Genital Psoriasis

Interventions: Drug: Ixekizumab
Drug: Placebo

First Posted Date: 2016-03-24

Last Posted Date: 2019-09-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 149

Registration Number: NCT02718898

Locations: 🇺🇸
Modern Research Associates PLLC, Dallas, Texas, United States
🇺🇸
Menter Dermatology Research Institute, Dallas, Texas, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

and more 13 locations

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: LY3022855
Drug: Durvalumab
Drug: Tremelimumab

First Posted Date: 2016-03-24

Last Posted Date: 2023-10-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT02718911

Locations: 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium

and more 11 locations

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

Phase 1

Completed

Conditions: Dyslipidemias

Interventions: Drug: LY3202328
Drug: Placebo
Drug: Atorvastatin
Drug: Simvastatin

First Posted Date: 2016-03-21

Last Posted Date: 2021-05-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT02714569

Locations: 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Phase 2

Active, not recruiting

Conditions: Biliary Tract Cancer
Metastatic Cancer
Advanced Cancer

Interventions: Drug: Cisplatin
Drug: Ramucirumab
Drug: Merestinib
Drug: Placebo IV
Drug: Placebo Oral
Drug: Gemcitabine

First Posted Date: 2016-03-17

Last Posted Date: 2024-10-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 309

Registration Number: NCT02711553

Locations: 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
UCSF Medical Center at Mission Bay, San Francisco, California, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

and more 76 locations

Home Terms & Conditions Privacy Policy